Gennex Laboratories Ltd

Gennex Laboratories Ltd’s share price declined to a fresh 52-week low of ₹7.87 on 27 March 2026, marking a significant drop amid broader market weakness and company-specific headwinds. The stock has underperformed its sector and benchmark indices, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology industry.

Despite a broad market upswing, Gennex Laboratories Ltd has slipped to a fresh 52-week low of Rs 8.06 on 25 Mar 2026, marking a near 53% decline from its 52-week high of Rs 17.25. This divergence from the market rally highlights persistent headwinds for the micro-cap pharmaceutical player.

Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Gennex Laboratories Ltd’s share price declined sharply to a new 52-week low of Rs.8.3 on 23 March 2026, reflecting a significant underperformance relative to its sector and the broader market. The stock’s fall comes amid a challenging market environment and subdued company financial metrics, marking a notable shift from its previous Hold rating to a Sell by MarketsMOJO.

Gennex Laboratories Ltd has seen a significant shift in its valuation parameters, moving from an attractive to a very attractive rating, despite a challenging recent performance relative to the broader market. This change is underpinned by improved price-to-earnings and price-to-book value ratios, positioning the micro-cap pharmaceutical player as a compelling consideration within its sector.

Gennex Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has recorded a fresh 52-week low of Rs.9.3 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its valuation and performance metrics.

Gennex Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.9.61 today, marking a significant decline amid broader market weakness and sectoral underperformance.

Gennex Laboratories Ltd’s stock declined to a fresh 52-week low of Rs.9.9 on 12 Mar 2026, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector and broader market weakness. The stock underperformed its sector and key indices, continuing a downward trend that has persisted over the past year.

Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Gennex Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.9.92 today, marking a significant decline amid broader market fluctuations and sectoral underperformance.

Gennex Laboratories Ltd’s shares declined sharply to a new 52-week low of Rs.10.1 on 9 March 2026, marking a significant downturn amid broader market weakness and company-specific performance concerns. The stock has underperformed its sector and the broader market over the past year, reflecting a challenging period for the pharmaceutical and biotechnology firm.

Gennex Laboratories Ltd’s shares declined to a fresh 52-week low of Rs.10.36 on 2 Mar 2026, marking a significant milestone in the stock’s downward trajectory over the past year. This new low reflects ongoing pressures within the Pharmaceuticals & Biotechnology sector and highlights the stock’s underperformance relative to broader market indices.

Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Gennex Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its quality rating downgraded from good to average as of 19 Jan 2026. This shift reflects changes in key business fundamentals including return ratios, debt levels, and growth consistency, prompting a reassessment of its investment appeal amid a challenging market environment.

Gennex Laboratories Limited, a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹299.00 crores, presents a complex investment narrative where impressive annual growth figures clash with deteriorating near-term momentum and bearish technical indicators. Trading at ₹11.89 as of February 16, 2026, the stock has declined 3.02% in the latest session and now trades 31.07% below its 52-week high of ₹17.25, reflecting mounting investor concerns about sustainability of the company's growth trajectory.

Gennex Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, posted a flat financial performance for the quarter ended December 2025, signalling a stabilisation after a period of decline. Despite the stagnant top-line growth, the company achieved record quarterly highs in net sales, operating profit, and earnings per share, reflecting improved operational efficiency amid rising interest costs and subdued return ratios.

Gennex Laboratories Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 13 February 2026, providing investors with the latest insights into the company’s performance and outlook.